Immix Biopharma NXC-201 hits 89% CR rate in AL amyloidosis trial
Immix Biopharma has reported an 89% complete response (CR) rate for its BCMA-targeted CAR-T therapy NXC-201 in an interim update from the 45-patient NEXICART-2 Phase 2 trial in relapsed/refractory AL amyloidosis. The independent review committee assessment found that 40 of 45 evaluable patients reached a CR, with the remaining four already testing MRD-negative in bone marrow, a status the company says has historically converted to full CR within one year of treatment.
Should all four MRD-negative patients follow that trajectory, the CR rate would rise to 98%, or 44 of 45 patients. No relapses have been observed to date among patients who achieved either CR or MRD-negativity, and the company reports no cases of neurotoxicity or enterocolitis, two adverse events that have complicated the broader CAR-T field.
Clinical and regulatory context
NEXICART-2 (NCT06097832) is a multi-site US Phase 2 study with a registrational design. Immix is targeting a Biologics Licence Application (BLA) submission in mid-2027, alongside a final trial readout. NXC-201 carries FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy status, as well as Orphan Drug Designation from both the FDA and the European Medicines Agency. Those designations will afford the company more frequent FDA dialogue and potentially faster review, though they do not guarantee approval.
Chief executive Ilya Rachman positioned the therapy as a potential one-and-done treatment for a disease that currently demands years of continuous management. "Today, patients with AL amyloidosis face years of burdensome, continuous treatment," he said. "As a potential one-and-done treatment option, NXC-201 could liberate patients from that burden." Gabriel Morris, the company's president, noted that the CR rate has continued to climb even as patient numbers more than doubled, which he described as an encouraging signal of consistency across a broader, more heterogeneous population.
Market landscape and competitive setting
AL amyloidosis is caused by the aberrant overproduction of immunoglobulin light chains that accumulate in and damage vital organs including the heart, kidneys and liver. The relapsed/refractory patient population in the United States is estimated at roughly 30,500, growing at around 12% annually according to published analysis in Blood Cancer Journal. The broader amyloidosis market was valued at approximately $6.2 billion in 2025 and is projected to reach $6.6 billion in 2026, according to figures cited by Immix from Grand View Research.
The AL amyloidosis space has attracted interest from several developers pursuing anti-plasma cell strategies, given the disease's underlying biology overlaps with multiple myeloma. Daratumumab-based regimens are currently widely used in earlier lines, but options narrow considerably at relapse. BCMA-targeting, well validated in myeloma through both antibody-drug conjugates and CAR-T approaches, is a logical extension into the amyloidosis setting, and NXC-201's proprietary "digital filter" binder architecture is designed to reduce non-specific T-cell activation, a mechanism Immix says underpins the favourable safety profile seen so far.
With BLA submission less than a year away, the critical near-term question is whether the final 45-patient dataset holds at or near the interim CR rate and whether the durability of response is sustained. Investors will also be watching for organ response data, which in AL amyloidosis is a key measure of clinical benefit that regulators are likely to scrutinise alongside haematological endpoints.